Mirum Pharmaceuticals, Inc. MIRM Livmarli — Product sales, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mirum Pharmaceuticals, Inc.'s livmarli — product sales, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s livmarli — product sales, net?
- Mirum Pharmaceuticals, Inc. (MIRM) reported livmarli — product sales, net of $113.8M in Q1 2026.
- How has Mirum Pharmaceuticals, Inc.'s livmarli — product sales, net changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s livmarli — product sales, net increased by 55.4% year-over-year, from $73.22M to $113.8M.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s livmarli — product sales, net?
- Over 3 years (2021 to 2025), Mirum Pharmaceuticals, Inc.'s livmarli — product sales, net has grown at a 385.9% compound annual growth rate (CAGR), from $3.14M to $360.01M.
- What does livmarli — product sales, net mean?
- Represents the total revenue generated from the sale of a specific pharmaceutical product after accounting for returns, allowances, and rebates. This metric is a primary indicator of market adoption and commercial success for a therapeutic asset.